Tag: AstraZeneca
AstraZeneca signs an AI discovery pact worth up to $1.5B
AstraZeneca has signed a multi-year drug-discovery collaboration with the AI biotech insitro, a deal the companies value at up to…
Pathos AI bets $125M on ADC its agent platform flagged
Pathos AI is paying $125M upfront for an Alphamab Oncology ADC that its Foundry agent platform flagged, plus a new…
AstraZeneca taps AI to de-risk late-stage trials and speed up filings
AstraZeneca CEO Pascal Soriot said the company is using AI to de-risk late-stage clinical trials and accelerate regulatory submissions.
AI shrinks drug discovery timelines with data-driven biologics design
MIT Technology Review explores how AstraZeneca and others use AI to compress drug discovery and target previously untreatable diseases.